Russo A - Search Results

1

Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.

Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E; Spartacuss Group. Fotia G, et al. Among authors: russo a. Clin Genitourin Cancer. 2024 Oct;22(5):102185. doi: 10.1016/j.clgc.2024.102185. Epub 2024 Aug 9. Clin Genitourin Cancer. 2024. PMID: 39217072 Free article.

2

A phase II study of carboplatin and paclitaxel as first line chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC).

Giorgio CG, Pappalardo A, Russo A, Giuffrida D, Santini D, Petralia G, Castorina S, Nunzio R, Failla G, Bordonaro R. Giorgio CG, et al. Among authors: russo a. Lung Cancer. 2006 Mar;51(3):357-62. doi: 10.1016/j.lungcan.2005.10.023. Epub 2006 Jan 9. Lung Cancer. 2006. PMID: 16406602 Clinical Trial.

3

Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.

Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G, Rocci L, Rosaria VM, Gebbia N, Tonini G. Vincenzi B, et al. Among authors: russo a. Pharmacogenomics. 2007 Apr;8(4):319-27. doi: 10.2217/14622416.8.4.319. Pharmacogenomics. 2007. PMID: 17391070 Clinical Trial.

4

Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.

Vincenzi B, Santini D, Galluzzo S, Russo A, Fulfaro F, Silletta M, Battistoni F, Rocci L, Zobel BB, Adamo V, Dicuonzo G, Tonini G. Vincenzi B, et al. Among authors: russo a. Clin Cancer Res. 2008 Jul 1;14(13):4219-24. doi: 10.1158/1078-0432.CCR-08-0077. Clin Cancer Res. 2008. PMID: 18594003 Free article.

5

Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis.

Russo A, Rizzo S, Fulfaro F, Adamo V, Santini D, Vincenzi B, Gebbia N, Carreca I. Russo A, et al. Cancer. 2009 May 1;115(9):1924-31. doi: 10.1002/cncr.24207. Cancer. 2009. PMID: 19235250 Free article.

6

Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial.

Vincenzi B, Santini D, Russo A, Spoto C, Venditti O, Gasparro S, Rizzo S, Zobel BB, Caricato M, Valeri S, Coppola R, Tonini G. Vincenzi B, et al. Among authors: russo a. Cancer. 2009 Oct 15;115(20):4849-56. doi: 10.1002/cncr.24540. Cancer. 2009. PMID: 19626652 Free article. Clinical Trial.

7

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.

Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, Rizzo S, Venditti O, Frezza AM, Caraglia M, Colucci G, Del Prete S, Tonini G. Vincenzi B, et al. Among authors: russo a. Oncologist. 2010;15(1):85-92. doi: 10.1634/theoncologist.2009-0143. Epub 2010 Jan 5. Oncologist. 2010. PMID: 20051477 Free PMC article.

8

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Rizzo S, et al. Among authors: russo a. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Cancer Treat Rev. 2010. PMID: 21129611 Review.

9

PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.

Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, Tonini G. Vincenzi B, et al. Among authors: russo a. J Cell Physiol. 2012 Mar;227(3):927-33. doi: 10.1002/jcp.22801. J Cell Physiol. 2012. PMID: 21503888

10

PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.

Vincenzi B, Santini D, Schiavon G, Frezza AM, Silletta M, Crucitti P, Casali P, Dei Tos AP, Rossi S, Rizzo S, Badalamenti G, Tomasino RM, Russo A, Butrynski JE, Tonini G. Vincenzi B, et al. Among authors: russo a. J Cell Physiol. 2012 Apr;227(4):1657-62. doi: 10.1002/jcp.22889. J Cell Physiol. 2012. PMID: 21678421

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

4,593 results

Search Page

Filters